Ixinity market could grow through 2030 as hemophilia B treatment demand rises

The Business Research Company says the global Ixinity market is set for steady growth through 2030, driven by more hemophilia diagnoses, aging populations and broader use of home-based care. North America leads the market now, while Asia-Pacific is expected to grow the fastest.

Why it matters: - Ixinity is a recombinant factor IX used to prevent and control bleeding in people with hemophilia B. - Growth in the market signals continued demand for specialized rare-disease treatments, especially as diagnosis rates rise and care shifts toward longer-acting and home-based options.

What happened: - The Business Research Company published its Ixinity Market Segmentation Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report covers market size, growth drivers, regional share and forecast trends for Ixinity through 2035. - The company also published a free sample of the report and a full market report.

The details: - Ixinity replaces deficient or missing clotting factor IX in patients with hemophilia B. - The therapy is administered by intravenous infusion. - The product is positioned as a long-acting treatment designed to reduce infusion frequency. - Historical market growth has been driven by hemophilia B prevalence, limits of plasma-derived clotting factors, recombinant technology advances, better hospital bleeding management and higher diagnosis rates. - Forecast growth is expected to come from extended half-life therapies, broader homecare treatment, more hemophilia awareness, supportive reimbursement policies for rare diseases and clotting-factor engineering improvements. - Key market trends include a shift toward long-acting factor IX therapies, more prophylactic care, more personalized bleeding-disorder management, growth in home infusion programs and higher purity in recombinant proteins. - The World Federation of Hemophilia said in October 2023 that hemophilia affects about 17.1 males per 100,000 for hemophilia A and 3.8 males per 100,000 for hemophilia B. - The same data set puts the global hemophilia population at about 830,895 patients, including 282,266 severe cases and more than 257,146 confirmed cases. - Confirmed cases include 208,957 hemophilia A patients and 42,203 hemophilia B patients, plus more than 100,000 cases of von Willebrand disease. - North America held the largest share of the Ixinity market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The report points to a market shaped less by one product change and more by a broader shift in hemophilia care: earlier diagnosis, longer treatment coverage and more flexible delivery outside hospitals. - An aging population adds pressure for durable therapies that can reduce bleeding risk while supporting older patients with chronic disease management. - The report also highlights demographic demand in the U.S., where the Population Reference Bureau projects Americans aged 65 and older will rise from 58 million in 2022 to 82 million by 2050. - That increase would lift the 65-plus share of the U.S. population from 17% to 23%.

What's next: - The market is likely to track adoption of extended half-life factor IX products and greater use of prophylactic treatment. - Reimbursement policy, home infusion expansion and product engineering advances will shape how quickly the market expands through 2035. - The report says its 2026 editions now include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards, hotspot infographics and updated trend analysis.

The bottom line: - Ixinity sits in a niche market with steady demand fundamentals and clear growth tailwinds, but future gains will depend on how quickly newer hemophilia therapies and care models scale globally.